Written | 2000-10 | Franck Viguié |
Laboratoire de Cytogenetique - Service d'Hematologie Biologique, Hopital Hotel-Dieu - 75181 Paris Cedex 04, France | ||
Updated | 2014-05 | Andrea Rabellino, Pier Paolo Scaglioni |
Division of Hematology, Oncology, Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA |
Identity |
Alias_symbol (synonym) | MYL |
TRIM19 | |
RNF71 | |
Other alias | |
HGNC (Hugo) | PML |
LocusID (NCBI) | 5371 |
Atlas_Id | 41 |
Location | 15q24.1 [Link to chromosome band 15q24] |
Location_base_pair | Starts at 73994673 and ends at 74036394 bp from pter ( according to hg19-Feb_2009) [Mapping PML.png] |
![]() | |
Top: Courtesy Mariano Rocchi, Resources for Molecular Cytogenetics. Bottom: Metaphase FISH analysis of PML (green); red dots indicate centromere of chromosome 15 (Subramaniyam et al., 2006). | |
Fusion genes (updated 2017) | Data from Atlas, Mitelman, Cosmic Fusion, Fusion Cancer, TCGA fusion databases with official HUGO symbols (see references in chromosomal bands) |
CAMSAP3 (19p13.2) / PML (15q24.1) | MYH9 (22q12.3) / PML (15q24.1) | PAX5 (9p13.2) / PML (15q24.1) | |
PML (15q24.1) / MAPK1IP1L (14q22.3) | PML (15q24.1) / PAX5 (9p13.2) | PML (15q24.1) / PML (15q24.1) | |
PML (15q24.1) / POLN (4p16.3) | PML (15q24.1) / RAB40B (17q25.3) | PML (15q24.1) / RARA (17q21.2) | |
RAB40B (17q25.3) / PML (15q24.1) | RARA (17q21.2) / PML (15q24.1) |
DNA/RNA |
![]() | |
Structural organization of PML human gene (Nisole et al., 2013). | |
Description | PML is composed of 9 exons. Exons 7 and 8 can be divided into exons 7a, 7b, 8a and 8b. |
Transcription | Transcription of PML generates 22 transcripts (splice variants) with at least 11 different isoforms (PMLI, PMLIa, PMLII, PMLIIa, PMLIII, PMLIV, PMLIVa, PMLV, PMLVI, PMLVIIa, PMLVIIb). Names of PML isoforms are based on the original nomenclature defined by Jensen et al., 2001. |
Pseudogene | No pseudogenes have been reported so far. |
Protein |
![]() | |
Schematic representation of PML isoforms (Nisole et al., 2013). | |
Description | Alternative splicing of PML gives rise to several isoforms with different molecular weight: PMLI is the longest isoform and is composed of 882 amino acids, while the shortest is PMLVIIb (435 amino acids). PML belongs to the family of the tripartite motif (TRIM). The RBCC/TRIM motif is present in all PML isoforms and is encoded by the exons 1-3. The RBCC domain is composed of a RING finger domain (R), two B-boxes domains (B1 and B2) and an α-helical coiled-coil domain (CC). The RING finger motif is a conserved cysteine-rich zinc-binding domain found in several classes of proteins. The RING domain of PML is involved in the formation of the PML nuclear bodies (PML-NBs, see below) and in several others PML functions. Adjacent to the RING domain lay two cysteine-rich domains named B-boxes: these two domains have been proposed to work as second zinc-binding domain and they are involved in PML-NBs formation and in several others PML functions. The coiled-coil domain mediate PML homo- and hetero-dimerization. The CC domain is also essential for PML-NBs formation and PML functions. A nuclear localization signal (NLS) is present in the isoforms but not in PMLVIIb. The SUMO interacting motif (SIM) of PML is required for the recognition and binding of SUMOylated proteins (Jensen et al., 2001; Nisole et al., 2013). The SIM domain also contains the PML degron, involved in the CK2-dependent PML degradation (Scaglioni et al., 2006). PML undergoes several post-translational modifications. Several kinases phosphorylate PML on serine and threonine residues regulating its functions (Bernardi et al., 2004; Hayakawa and Privalsky, 2004; Scaglioni et al., 2006; Yang et al., 2006). SUMOylation is the most intensely studied post-translational modification of PML. Both SUMO1 and SUMO2/SUMO3 bind covalently to PML. SUMOylation facilitates PML-NBs formation promoting tumor suppressive response PML-dependent, but also promotes leukemogenesis by the SUMOylation of PML-RARA. Finally, SUMOylation also promotes ubiquitin-mediate degradation of PML and PML-RARA (Fu et al., 2005; Shen et al., 2006; Lallemand-Breitenbach et al., 2008; Kamitani et al., 1998a; Kamitani et al., 1998b; Rabellino et al., 2012). Ubiquitination regulates PML functions and activity and deregulation of PML appears to be the common mechanism accounting for PML loss in tumors (reviewed in Rabellino and Scaglioni, 2013). Finally, PML can be also acetylated (Hayakawa et al., 2008). PML is the major constituent of the PML-NBs. PML-NBs are highly dynamic nuclear structures tightly bound to the nuclear matrix. Several functions of PML are related to the PML-NBs functions (reviewed in Bernardi et al., 2007). More than 150 different proteins have been shown to localize into PML-NBs (Van Damme et al., 2010). |
![]() | |
Schematic representation of PML isoform IV protein domains. R = RING-finger domains, aa 55-91; B1, B2 = B-boxes 1 aa 124-166 and 2 aa 184-228; CC = α-helical coiled-coil domain, aa 233-360; N = nuclear localization signal, aa 428-442; SIM = SUMO interacting motif, 508-518; D = degron. The three major SUMOylation sites (K60, K160 and K442) are indicated, as well as the major phosphorylation sites (T28, S36, S40, S480, T482, S517). | |
Expression | PML is ubiquitously expressed. |
Localisation | Nuclear (PMLI-VI) and cytoplasmic (PMLVIIb). |
Function | PML has been implicated in several cellular functions. Cellular senescence: PML is a key regulator of cellular senescence. PML is involved in oncogenic-induced senescence (OIS) K-RAS dependent in a p53 dependent way (de Stanchina et al., 2004; Ferbeyre et al., 2000; Pearson et al., 2000; Scaglioni et al., 2012). PML is also involved in Rb-dependent senescence (Mallette et al., 2004). Apoptosis: PML promotes apoptosis primarily by its ability to interact with p53 (Wang et al., 1998). Moreover, a pro-apoptotic function has been also attributed to the cytoplasmic isoform of PML (Giorgi et al., 2010). Neoangiogenesis: PML represses HIF1 transcription, blocking de novo angiogenesis (Bernardi et al., 2006). Cell migration: PML is involved in the regulation of cell migration by the negatively regulating of β-1 integrins (Reineke et al., 2010). DNA damage response: several proteins involved in DNA repair have been report to reside into PML-NBs. Therefore, PML is also involved in DNA-repair, even though the mechanisms are still not completely clear (reviewed in Dellaire and Bazett-Jones, 2004). Anti-viral response: several viral proteins interact with PML and the PML-NBs; moreover, several reports implicate PML and PML-NBs in anti-viral response (reviewed in Geoffroy and Chelbi-Alix, 2011). Hematopoietic stem cell maintenance: PML has been reported being involved in hematopoietic stem cell maintenance by the regulation of the fatty acid oxidation (Ito et al., 2008; Ito et al., 2012). Several functions of PML are related to its ability to form PML-NBs. PML-NBs have been involved in tumor suppression, senescence and apoptosis, DNA-damage response, cell migration, neoangiogenesis and anti-viral response (reviewed in Bernardi et al., 2007). |
Homology | PML is conserved in Amniota (source: HomoloGene). |
Mutations |
Note | PML-RARA is the product of the chromosomal translocation t(15;17) and it causes acute promyelocytic leukemia (APL) (de Thé et al., 1990; Goddard et al., 1991; Kakizuka et al., 1991; Pandolfi et al., 1991). |
![]() | |
Schematic representation of the mutations type of human PML found in human tumor samples (source COSMIC). | |
Germinal | No germinal mutations of PML have been reported. |
Somatic | At least 65 different somatic mutations have been described. All the informations in this regard can be found at the COSMIC website. |
Implicated in |
Note | |
Entity | Acute promyelocytic leukemia (APL) |
Note | (de Thé et al., 1990; Goddard et al., 1991; Kakizuka et al., 1991; Pandolfi et al., 1991) |
Disease | The balanced chromosomal translocation t(15;17)(q24;q21) causes APL by driving the synthesis of the PML-RARA oncoprotein. This translocation drives the production of three different PML-RARA variants, depending on the length of the PML module: a short variant PML(S)-RARA, an intermediate variant PML(V)-RARA and a long variant PML(L)-RARA. Generally, 70% of the APL patients carry the PML(L)-RARA variant, followed by the PML(S)-RARA variant (20%) and the PML(V)-RARA (10%) (Melnick and Licht, 1999). PML staining in APL cells show a characteristic pattern commonly named "microspeckles" due to the fact that PML-RARA disrupts the PML-NBs. PML-RARA acts as a transcriptional repressor of RARA target genes. At the same time PML-RARA physically interacts with PML, impairing its tumor-suppressive functions. Combined, these features lead to the aberrant self-renewal of hematopoietic stem cells and block of differentiation of myeloid precursor cells at the promyelocytic stage (de Thé et al., 2012). APL is a distinct subtype of acute myeloid leukemia (AML), is a rare condition though extremely aggressive and malignant. Clinically, APL symptoms tend to be similar to AML. APL is characterized by a severe coagulopathy, including disseminated intravascular coagulation (DIC). |
Prognosis | APL is normally treated with the combination of retinoic acid (ATRA) and arsenic trioxide (ATO). This therapy leads to the remission of the disease in more than 90% of the cases. Notably, APL was the first malignant disease cured with targeted therapy (Lo-Coco et al., 2013). |
Entity | B-cell acute lymphoblastic leukemia (B-ALL) |
Note | (Nebral et al., 2007; Qiu et al., 2011; Kurahashi et al., 2011) |
Disease | The transcription factor PAX5 is required for development and maintenance of B-cell. Several chromosomal translocations involving PAX5 have been described, including the t(9;15)(p13;q24) in which the 5' region of PAX5 is fused to PML. So far, two cases of B-ALL PAX5-PML-dependent have been reported. The fused PAX5-PML oncoprotein has a dominant-negative effect on both PML and PAX5, inhibiting PAX5 activation of B-cell specific genes and disrupting PML-NBs formation. |
Prognosis | Kurahashi and colleagues suggest that B-ALL PAX5-PML dependent could be treated with ATO (Kurahashi et al., 2011). |
Entity | Various cancers |
Note | Several reports indicate a reduced PML expression in several cancer types (Gurrieri et al., 2004; Rabellino et al., 2012; Rabellino and Scaglioni, 2013). |
Disease | PML protein expression was reduced or abolished in prostate adenocarcinomas (63% [95% confidence interval {CI} = 48% to 78%] and 28% [95% CI = 13% to 43%], respectively), colon adenocarcinomas (31% [95% CI = 22% to 40%] and 17% [95% CI = 10% to 24%]), breast carcinomas (21% [95% CI = 8% to 34%] and 31% [95% CI = 16% to 46%]), lung carcinomas (36% [95% CI = 15% to 57%] and 21% [95% = 3% to 39%]), lymphomas (14% [95% CI = 10% to 18%] and 69% [95% CI = 63% to 75%]), CNS tumors (24% [95% CI = 13% to 35%] and 49% [95% CI = 36% to 62%]), and germ cell tumors (36% [95% CI = 24% to 48%] and 48% [95% CI = 36% to 60%]) but not in thyroid or adrenal carcinomas (Gurrieri et al., 2004). In all the cases, PML mRNA levels are comparable to the healthy tissues and the PML gene is rarely mutated, but the protein levels of PML are reduced. This correlates with several reports that underline the role of PML degradation in tumor progression and maintenance (reviewed in Rabellino and Scaglioni, 2013). |
Prognosis | In most of the cases, loss of PML is associated with tumor progression, like was reported for prostate cancer, breast cancer and CNS tumors (Gurrieri et al., 2004). |
Breakpoints |
![]() | |
Note | Breakpoint at q24, responsible of translocation t(15;17)(q24;q21). |
Bibliography |
Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. |
Bernardi R, Pandolfi PP. |
Nat Rev Mol Cell Biol. 2007 Dec;8(12):1006-16. (REVIEW) |
PMID 17928811 |
PML nuclear bodies: dynamic sensors of DNA damage and cellular stress. |
Dellaire G, Bazett-Jones DP. |
Bioessays. 2004 Sep;26(9):963-77. (REVIEW) |
PMID 15351967 |
PML is induced by oncogenic ras and promotes premature senescence. |
Ferbeyre G, de Stanchina E, Querido E, Baptiste N, Prives C, Lowe SW. |
Genes Dev. 2000 Aug 15;14(16):2015-27. |
PMID 10950866 |
Stabilization of PML nuclear localization by conjugation and oligomerization of SUMO-3. |
Fu C, Ahmed K, Ding H, Ding X, Lan J, Yang Z, Miao Y, Zhu Y, Shi Y, Zhu J, Huang H, Yao X. |
Oncogene. 2005 Aug 18;24(35):5401-13. |
PMID 15940266 |
Role of promyelocytic leukemia protein in host antiviral defense. |
Geoffroy MC, Chelbi-Alix MK. |
J Interferon Cytokine Res. 2011 Jan;31(1):145-58. doi: 10.1089/jir.2010.0111. Epub 2011 Jan 3. (REVIEW) |
PMID 21198351 |
PML regulates apoptosis at endoplasmic reticulum by modulating calcium release. |
Giorgi C, Ito K, Lin HK, Santangelo C, Wieckowski MR, Lebiedzinska M, Bononi A, Bonora M, Duszynski J, Bernardi R, Rizzuto R, Tacchetti C, Pinton P, Pandolfi PP. |
Science. 2010 Nov 26;330(6008):1247-51. doi: 10.1126/science.1189157. Epub 2010 Oct 28. |
PMID 21030605 |
Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia. |
Goddard AD, Borrow J, Freemont PS, Solomon E. |
Science. 1991 Nov 29;254(5036):1371-4. |
PMID 1720570 |
Loss of the tumor suppressor PML in human cancers of multiple histologic origins. |
Gurrieri C, Capodieci P, Bernardi R, Scaglioni PP, Nafa K, Rush LJ, Verbel DA, Cordon-Cardo C, Pandolfi PP. |
J Natl Cancer Inst. 2004 Feb 18;96(4):269-79. |
PMID 14970276 |
Acetylation of PML is involved in histone deacetylase inhibitor-mediated apoptosis. |
Hayakawa F, Abe A, Kitabayashi I, Pandolfi PP, Naoe T. |
J Biol Chem. 2008 Sep 5;283(36):24420-5. doi: 10.1074/jbc.M802217200. Epub 2008 Jul 11. |
PMID 18621739 |
PML targeting eradicates quiescent leukaemia-initiating cells. |
Ito K, Bernardi R, Morotti A, Matsuoka S, Saglio G, Ikeda Y, Rosenblatt J, Avigan DE, Teruya-Feldstein J, Pandolfi PP. |
Nature. 2008 Jun 19;453(7198):1072-8. doi: 10.1038/nature07016. Epub 2008 May 11. |
PMID 18469801 |
A PML-PPAR-delta pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance. |
Ito K, Carracedo A, Weiss D, Arai F, Ala U, Avigan DE, Schafer ZT, Evans RM, Suda T, Lee CH, Pandolfi PP. |
Nat Med. 2012 Sep;18(9):1350-8. |
PMID 22902876 |
PML protein isoforms and the RBCC/TRIM motif. |
Jensen K, Shiels C, Freemont PS. |
Oncogene. 2001 Oct 29;20(49):7223-33. (REVIEW) |
PMID 11704850 |
Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. |
Kakizuka A, Miller WH Jr, Umesono K, Warrell RP Jr, Frankel SR, Murty VV, Dmitrovsky E, Evans RM. |
Cell. 1991 Aug 23;66(4):663-74. |
PMID 1652368 |
Covalent modification of PML by the sentrin family of ubiquitin-like proteins. |
Kamitani T, Nguyen HP, Kito K, Fukuda-Kamitani T, Yeh ET. |
J Biol Chem. 1998b Feb 6;273(6):3117-20. |
PMID 9452416 |
PAX5-PML acts as a dual dominant-negative form of both PAX5 and PML. |
Kurahashi S, Hayakawa F, Miyata Y, Yasuda T, Minami Y, Tsuzuki S, Abe A, Naoe T. |
Oncogene. 2011 Apr 14;30(15):1822-30. doi: 10.1038/onc.2010.554. Epub 2011 Jan 10. |
PMID 21217775 |
Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. |
Lallemand-Breitenbach V, Jeanne M, Benhenda S, Nasr R, Lei M, Peres L, Zhou J, Zhu J, Raught B, de The H. |
Nat Cell Biol. 2008 May;10(5):547-55. doi: 10.1038/ncb1717. Epub 2008 Apr 13. |
PMID 18408733 |
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. |
Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, Ferrara F, Fazi P, Cicconi L, Di Bona E, Specchia G, Sica S, Divona M, Levis A, Fiedler W, Cerqui E, Breccia M, Fioritoni G, Salih HR, Cazzola M, Melillo L, Carella AM, Brandts CH, Morra E, von Lilienfeld-Toal M, Hertenstein B, Wattad M, Lubbert M, Hanel M, Schmitz N, Link H, Kropp MG, Rambaldi A, La Nasa G, Luppi M, Ciceri F, Finizio O, Venditti A, Fabbiano F, Dohner K, Sauer M, Ganser A, Amadori S, Mandelli F, Dohner H, Ehninger G, Schlenk RF, Platzbecker U; Gruppo Italiano Malattie Ematologiche dell'Adulto; German-Austrian Acute Myeloid Leukemia Study Group; Study Alliance Leukemia. |
N Engl J Med. 2013 Jul 11;369(2):111-21. doi: 10.1056/NEJMoa1300874. |
PMID 23841729 |
Human fibroblasts require the Rb family of tumor suppressors, but not p53, for PML-induced senescence. |
Mallette FA, Goumard S, Gaumont-Leclerc MF, Moiseeva O, Ferbeyre G. |
Oncogene. 2004 Jan 8;23(1):91-9. |
PMID 14712214 |
Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. |
Melnick A, Licht JD. |
Blood. 1999 May 15;93(10):3167-215. (REVIEW) |
PMID 10233871 |
Identification of PML as novel PAX5 fusion partner in childhood acute lymphoblastic leukaemia. |
Nebral K, Konig M, Harder L, Siebert R, Haas OA, Strehl S. |
Br J Haematol. 2007 Oct;139(2):269-74. |
PMID 17897302 |
Differential Roles of PML Isoforms. |
Nisole S, Maroui MA, Mascle XH, Aubry M, Chelbi-Alix MK. |
Front Oncol. 2013 May 22;3:125. doi: 10.3389/fonc.2013.00125. eCollection 2013. |
PMID 23734343 |
Structure and origin of the acute promyelocytic leukemia myl/RAR alpha cDNA and characterization of its retinoid-binding and transactivation properties. |
Pandolfi PP, Grignani F, Alcalay M, Mencarelli A, Biondi A, LoCoco F, Grignani F, Pelicci PG. |
Oncogene. 1991 Jul;6(7):1285-92. |
PMID 1650447 |
PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. |
Pearson M, Carbone R, Sebastiani C, Cioce M, Fagioli M, Saito S, Higashimoto Y, Appella E, Minucci S, Pandolfi PP, Pelicci PG. |
Nature. 2000 Jul 13;406(6792):207-10. |
PMID 10910364 |
The reduced and altered activities of PAX5 are linked to the protein-protein interaction motif (coiled-coil domain) of the PAX5-PML fusion protein in t(9;15)-associated acute lymphocytic leukemia. |
Qiu JJ, Chu H, Lu X, Jiang X, Dong S. |
Oncogene. 2011 Feb 24;30(8):967-77. doi: 10.1038/onc.2010.473. Epub 2010 Oct 25. |
PMID 20972455 |
PML Degradation: Multiple Ways to Eliminate PML. |
Rabellino A, Scaglioni PP. |
Front Oncol. 2013 Mar 22;3:60. doi: 10.3389/fonc.2013.00060. eCollection 2013. |
PMID 23526763 |
Promyelocytic leukemia protein controls cell migration in response to hydrogen peroxide and insulin-like growth factor-1. |
Reineke EL, Liu Y, Kao HY. |
J Biol Chem. 2010 Mar 26;285(13):9485-92. doi: 10.1074/jbc.M109.063362. Epub 2010 Jan 25. |
PMID 20100838 |
Translation-dependent mechanisms lead to PML upregulation and mediate oncogenic K-RAS-induced cellular senescence. |
Scaglioni PP, Rabellino A, Yung TM, Bernardi R, Choi S, Konstantinidou G, Nardella C, Cheng K, Pandolfi PP. |
EMBO Mol Med. 2012 Jul;4(7):594-602. doi: 10.1002/emmm.201200233. Epub 2012 Mar 21. |
PMID 22359342 |
The mechanisms of PML-nuclear body formation. |
Shen TH, Lin HK, Scaglioni PP, Yung TM, Pandolfi PP. |
Mol Cell. 2006 Nov 3;24(3):331-9. |
PMID 17081985 |
Do RARA/PML fusion gene deletions confer resistance to ATRA-based therapy in patients with acute promyelocytic leukemia? |
Subramaniyam S, Nandula SV, Nichols G, Weiner M, Satwani P, Alobeid B, Bhagat G, Murty VV. |
Leukemia. 2006 Dec;20(12):2193-5. Epub 2006 Sep 28. |
PMID 17008891 |
A manually curated network of the PML nuclear body interactome reveals an important role for PML-NBs in SUMOylation dynamics. |
Van Damme E, Laukens K, Dang TH, Van Ostade X. |
Int J Biol Sci. 2010 Jan 12;6(1):51-67. (REVIEW) |
PMID 20087442 |
PML is essential for multiple apoptotic pathways. |
Wang ZG, Ruggero D, Ronchetti S, Zhong S, Gaboli M, Rivi R, Pandolfi PP. |
Nat Genet. 1998 Nov;20(3):266-72. |
PMID 9806545 |
Promyelocytic leukemia activates Chk2 by mediating Chk2 autophosphorylation. |
Yang S, Jeong JH, Brown AL, Lee CH, Pandolfi PP, Chung JH, Kim MK. |
J Biol Chem. 2006 Sep 8;281(36):26645-54. Epub 2006 Jul 11. |
PMID 16835227 |
PML is a direct p53 target that modulates p53 effector functions. |
de Stanchina E, Querido E, Narita M, Davuluri RV, Pandolfi PP, Ferbeyre G, Lowe SW. |
Mol Cell. 2004 Feb 27;13(4):523-35. |
PMID 14992722 |
The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. |
de The H, Chomienne C, Lanotte M, Degos L, Dejean A. |
Nature. 1990 Oct 11;347(6293):558-61. |
PMID 2170850 |
The cell biology of disease: Acute promyelocytic leukemia, arsenic, and PML bodies. |
de The H, Le Bras M, Lallemand-Breitenbach V. |
J Cell Biol. 2012 Jul 9;198(1):11-21. doi: 10.1083/jcb.201112044. (REVIEW) |
PMID 22778276 |
Citation |
This paper should be referenced as such : |
A Rabellino, PP Scaglioni |
PML (promyelocytic leukemia) |
Atlas Genet Cytogenet Oncol Haematol. 2015;19(1):44-49. |
Free journal version : [ pdf ] [ DOI ] |
On line version : http://AtlasGeneticsOncology.org/Genes/PMLID41.html |
History of this paper: |
Viguié, F. PML (promyelocytic leukemia). Atlas Genet Cytogenet Oncol Haematol. 2000;4(4):193-194. |
http://documents.irevues.inist.fr/bitstream/handle/2042/37669/10-2000-PMLID41.pdf |
Other Leukemias implicated (Data extracted from papers in the Atlas) [ 3 ] |
M3/M3v acute myeloid leukemia (AML M3/M3v) ::Acute promyelocytic leukemia (APL) ::Acute promyelocytic leukemia (APL) PML/RARA t(9;15)(p13;q24) PAX5/PML t(15;17)(q24;q21) PML/RARA |
Other Solid tumors implicated (Data extracted from papers in the Atlas) [ 1 ] |
t(4;15)(p16;q22) PML/POLN
|
External links |
REVIEW articles | automatic search in PubMed |
Last year publications | automatic search in PubMed |
© Atlas of Genetics and Cytogenetics in Oncology and Haematology | indexed on : Wed Nov 13 21:50:02 CET 2019 |
For comments and suggestions or contributions, please contact us